Table 1.

Clinical characteristics of patients and suspected adverse reaction (n = 119).

Clinical characteristic	n (%)
Sex
Male	67 (56.3)
Female	52 (43.7)
Type of ALL
BCP-LLA	101 (84.9)
T-LLA	18 (15.1)
Risk classification
Standard	27 (22.7)
Medium	43 (36.1)
High	49 (41.2)
SRA during the asparaginase infusion
Yes	72 (60.5)
No	47 (39.5)

BCP-LLA: acute lymphoblastic leukemia of B-cell precursors; T-ALL: acute T-cell lymphoblastic leukemia; SRA: suspected adverse reaction.